Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and ...

The company expects the European Commission (EC) to make a final decision on the marketing authorization in June 2025.

Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

EMA committee recommends approval of argenx’s Vyvgart subcutaneous injection for chronic inflammatory demyelinating polyneuropathy: Amsterdam, the Netherlands Tuesday, April 29, ...

Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news ...

Acurx Pharmaceuticals (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced ...

View Halozyme Therapeutics, Inc. (HALO) current and estimated P/E ratio data provided by Seeking Alpha.

Washington’s NFL franchise is set to return to the nation’s capital as part of an agreement between the organization and the ...